Name: Global Ophthalmology Disorders Drug Market Insights, Forecast to 2035
Brand: Extent Research
Price: 3500 USD
Availability: InStock
Rating: 4.9 (195 reviews)

Global Ophthalmology Disorders Drug Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

The latest research report on global Ophthalmology Disorders Drug market was conducted across variety of competitive players in various regions in order to provide realistic and foolproof data. The report offers all the quantifiable and qualitative data based on vital aspects including market opportunities, challenges, risks, competitors, regional players, and latest development trends. In the report, the top players in market, Sanofi, Bayer, Bausch + Lomb, Novartis, Usher Syndrome, Takeda Pharmaceutical, Roche, Pfizer, Allergan, Gilead Sciences, Kubota Pharmaceutical, Alkeus Pharmaceuticals, Astellas Pharma, Ferrer Corporate, Amgen Inc, Editas Medicine Inc, ProQR Therapeutics NV, ReNeuron, Amarantus BioScience, Ocugen, ReGenX Biosciences, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Okuvision, Second Sight Medical, Acucela, Stealth BioTherapeutics, Sun Pharma Advanced Research Company, AmpliPhi Biosciences, Applied Genetic Technologies, Asklepios BioPharmaceutical, Biovista, Spark Therapeutics, Caladrius Biosciences, Dompe Farmaceutici, Dormant Projects, Grupo Ferrer Internacional, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Ixchel Pharma, Khondrion, Mimetogen Pharmaceuticals, Mitotech, M’s Science, Nanovector, SanBio, are profiled. Another important point is that the report contains the import/export policies, market share & revenue, and business strategies details that tend to have a huge impact on the global Ophthalmology Disorders Drug market. Furthermore, the other relevant and valuable factors provided by the report include finances, product portfolio, investment planning, and marketing & business strategy.

Data provided by Extent Research. Source: https://www.extentresearch.com/ophthalmology-disorders-drug-market

The graphs and tables in the report help better understand the numerical and theoretical data associated with the market growth during the forecast period. Additionally, the regions North America, Europe, Asia Pacific, Latin America, Middle East & Africa, show the Ophthalmology Disorders Drug market to flourish and gain momentum during forecast period. The Ophthalmology Disorders Drug market is expected to boom in the regions basically due to the various government policies, high supply & demand, business tactics, and various technological developments. In the end, the report speaks more vibrantly about the market growth rate, growth drivers, and statistical increment during the foreseeable timeframe.

Segmentation of the Global Ophthalmology Disorders Drug Market:

By Product type

Oral, Injection, External Use,

by Application

Juvenile Macular Degeneration (Stargardt Disease), Leber Congenital Amaurosis (LCA), Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy), Usher Syndrome, Retinitis Pigmentosa (Retinitis),

Quantifiable data:

Breakdown data depending on diverse segmentation (Key players, Regions, Applications, & Others)
Market sales and growth rate (Historical, current, & forecast)
Market size, share, and revenue
Market pricing and supply & demand chain

Qualitative data:

Market overview
Ophthalmology Disorders Drug market growth influencers
Global Ophthalmology Disorders Drug market trends
Business policies and government regulations
Ophthalmology Disorders Drug market opportunities, challenges, and threats
Market entropy

Questions answered by the report:

What are the factors influencing the global Ophthalmology Disorders Drug market growth/
What is the expected growth rate of the Ophthalmology Disorders Drug market during the forecast period?
Which are the regions experiencing a boom in Ophthalmology Disorders Drug market?
What is expected market size and share during the forecast period?

Report Scope and Market Segmentation

ATTRIBUTES	Global Ophthalmology Disorders Drug Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Ophthalmology Disorders Drug Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2035
        1.2.2 Oral
        1.2.3 Injection
        1.2.4 External Use
    1.3 Market by Application
        1.3.1 Global Ophthalmology Disorders Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2035
        1.3.2 Juvenile Macular Degeneration (Stargardt Disease)
        1.3.3 Leber Congenital Amaurosis (LCA)
        1.3.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)
        1.3.5 Usher Syndrome
        1.3.6 Retinitis Pigmentosa (Retinitis)
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Ophthalmology Disorders Drug Market Perspective (2017-2035)
    2.2 Ophthalmology Disorders Drug Growth Trends by Region
        2.2.1 Ophthalmology Disorders Drug Market Size by Region: 2017 VS 2021 VS 2035
        2.2.2 Ophthalmology Disorders Drug Historic Market Size by Region (2017-2022)
        2.2.3 Ophthalmology Disorders Drug Forecasted Market Size by Region (2023-2035)
    2.3 Ophthalmology Disorders Drug Market Dynamics
        2.3.1 Ophthalmology Disorders Drug Industry Trends
        2.3.2 Ophthalmology Disorders Drug Market Drivers
        2.3.3 Ophthalmology Disorders Drug Market Challenges
        2.3.4 Ophthalmology Disorders Drug Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Ophthalmology Disorders Drug Players by Revenue
        3.1.1 Global Top Ophthalmology Disorders Drug Players by Revenue (2017-2022)
        3.1.2 Global Ophthalmology Disorders Drug Revenue Market Share by Players (2017-2022)
    3.2 Global Ophthalmology Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Ophthalmology Disorders Drug Revenue
    3.4 Global Ophthalmology Disorders Drug Market Concentration Ratio
        3.4.1 Global Ophthalmology Disorders Drug Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Ophthalmology Disorders Drug Revenue in 2021
    3.5 Ophthalmology Disorders Drug Key Players Head office and Area Served
    3.6 Key Players Ophthalmology Disorders Drug Product Solution and Service
    3.7 Date of Enter into Ophthalmology Disorders Drug Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmology Disorders Drug Breakdown Data by Type
    4.1 Global Ophthalmology Disorders Drug Historic Market Size by Type (2017-2022)
    4.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Type (2023-2035)
5 Ophthalmology Disorders Drug Breakdown Data by Application
    5.1 Global Ophthalmology Disorders Drug Historic Market Size by Application (2017-2022)
    5.2 Global Ophthalmology Disorders Drug Forecasted Market Size by Application (2023-2035)
6 North America
    6.1 North America Ophthalmology Disorders Drug Market Size (2017-2035)
    6.2 North America Ophthalmology Disorders Drug Market Size by Type
        6.2.1 North America Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        6.2.2 North America Ophthalmology Disorders Drug Market Size by Type (2023-2035)
        6.2.3 North America Ophthalmology Disorders Drug Market Share by Type (2017-2035)
    6.3 North America Ophthalmology Disorders Drug Market Size by Application
        6.3.1 North America Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        6.3.2 North America Ophthalmology Disorders Drug Market Size by Application (2023-2035)
        6.3.3 North America Ophthalmology Disorders Drug Market Share by Application (2017-2035)
    6.4 North America Ophthalmology Disorders Drug Market Size by Country
        6.4.1 North America Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        6.4.2 North America Ophthalmology Disorders Drug Market Size by Country (2023-2035)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Ophthalmology Disorders Drug Market Size (2017-2035)
    7.2 Europe Ophthalmology Disorders Drug Market Size by Type
        7.2.1 Europe Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        7.2.2 Europe Ophthalmology Disorders Drug Market Size by Type (2023-2035)
        7.2.3 Europe Ophthalmology Disorders Drug Market Share by Type (2017-2035)
    7.3 Europe Ophthalmology Disorders Drug Market Size by Application
        7.3.1 Europe Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        7.3.2 Europe Ophthalmology Disorders Drug Market Size by Application (2023-2035)
        7.3.3 Europe Ophthalmology Disorders Drug Market Share by Application (2017-2035)
    7.4 Europe Ophthalmology Disorders Drug Market Size by Country
        7.4.1 Europe Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        7.4.2 Europe Ophthalmology Disorders Drug Market Size by Country (2023-2035)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Ophthalmology Disorders Drug Market Size (2017-2035)
    8.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type
        8.2.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Type (2023-2035)
        8.2.3 Asia-Pacific Ophthalmology Disorders Drug Market Share by Type (2017-2035)
    8.3 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application
        8.3.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Application (2023-2035)
        8.3.3 Asia-Pacific Ophthalmology Disorders Drug Market Share by Application (2017-2035)
    8.4 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region
        8.4.1 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Ophthalmology Disorders Drug Market Size by Region (2023-2035)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Ophthalmology Disorders Drug Market Size (2017-2035)
    9.2 Latin America Ophthalmology Disorders Drug Market Size by Type
        9.2.1 Latin America Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        9.2.2 Latin America Ophthalmology Disorders Drug Market Size by Type (2023-2035)
        9.2.3 Latin America Ophthalmology Disorders Drug Market Share by Type (2017-2035)
    9.3 Latin America Ophthalmology Disorders Drug Market Size by Application
        9.3.1 Latin America Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        9.3.2 Latin America Ophthalmology Disorders Drug Market Size by Application (2023-2035)
        9.3.3 Latin America Ophthalmology Disorders Drug Market Share by Application (2017-2035)
    9.4 Latin America Ophthalmology Disorders Drug Market Size by Country
        9.4.1 Latin America Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        9.4.2 Latin America Ophthalmology Disorders Drug Market Size by Country (2023-2035)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Ophthalmology Disorders Drug Market Size (2017-2035)
    10.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type
        10.2.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Type (2023-2035)
        10.2.3 Middle East & Africa Ophthalmology Disorders Drug Market Share by Type (2017-2035)
    10.3 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application
        10.3.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Application (2023-2035)
        10.3.3 Middle East & Africa Ophthalmology Disorders Drug Market Share by Application (2017-2035)
    10.4 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country
        10.4.1 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Ophthalmology Disorders Drug Market Size by Country (2023-2035)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Sanofi
        11.1.1 Sanofi Company Details
        11.1.2 Sanofi Business Overview
        11.1.3 Sanofi Ophthalmology Disorders Drug Introduction
        11.1.4 Sanofi Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.1.5 Sanofi Recent Developments
    11.2 Bayer
        11.2.1 Bayer Company Details
        11.2.2 Bayer Business Overview
        11.2.3 Bayer Ophthalmology Disorders Drug Introduction
        11.2.4 Bayer Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.2.5 Bayer Recent Developments
    11.3 Bausch + Lomb
        11.3.1 Bausch + Lomb Company Details
        11.3.2 Bausch + Lomb Business Overview
        11.3.3 Bausch + Lomb Ophthalmology Disorders Drug Introduction
        11.3.4 Bausch + Lomb Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.3.5 Bausch + Lomb Recent Developments
    11.4 Novartis
        11.4.1 Novartis Company Details
        11.4.2 Novartis Business Overview
        11.4.3 Novartis Ophthalmology Disorders Drug Introduction
        11.4.4 Novartis Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.4.5 Novartis Recent Developments
    11.5 Usher Syndrome
        11.5.1 Usher Syndrome Company Details
        11.5.2 Usher Syndrome Business Overview
        11.5.3 Usher Syndrome Ophthalmology Disorders Drug Introduction
        11.5.4 Usher Syndrome Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.5.5 Usher Syndrome Recent Developments
    11.6 Takeda Pharmaceutical
        11.6.1 Takeda Pharmaceutical Company Details
        11.6.2 Takeda Pharmaceutical Business Overview
        11.6.3 Takeda Pharmaceutical Ophthalmology Disorders Drug Introduction
        11.6.4 Takeda Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.6.5 Takeda Pharmaceutical Recent Developments
    11.7 Roche
        11.7.1 Roche Company Details
        11.7.2 Roche Business Overview
        11.7.3 Roche Ophthalmology Disorders Drug Introduction
        11.7.4 Roche Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.7.5 Roche Recent Developments
    11.8 Pfizer
        11.8.1 Pfizer Company Details
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Ophthalmology Disorders Drug Introduction
        11.8.4 Pfizer Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.8.5 Pfizer Recent Developments
    11.9 Allergan
        11.9.1 Allergan Company Details
        11.9.2 Allergan Business Overview
        11.9.3 Allergan Ophthalmology Disorders Drug Introduction
        11.9.4 Allergan Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.9.5 Allergan Recent Developments
    11.10 Gilead Sciences
        11.10.1 Gilead Sciences Company Details
        11.10.2 Gilead Sciences Business Overview
        11.10.3 Gilead Sciences Ophthalmology Disorders Drug Introduction
        11.10.4 Gilead Sciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.10.5 Gilead Sciences Recent Developments
    11.11 Kubota Pharmaceutical
        11.11.1 Kubota Pharmaceutical Company Details
        11.11.2 Kubota Pharmaceutical Business Overview
        11.11.3 Kubota Pharmaceutical Ophthalmology Disorders Drug Introduction
        11.11.4 Kubota Pharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.11.5 Kubota Pharmaceutical Recent Developments
    11.12 Alkeus Pharmaceuticals
        11.12.1 Alkeus Pharmaceuticals Company Details
        11.12.2 Alkeus Pharmaceuticals Business Overview
        11.12.3 Alkeus Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.12.4 Alkeus Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.12.5 Alkeus Pharmaceuticals Recent Developments
    11.13 Astellas Pharma
        11.13.1 Astellas Pharma Company Details
        11.13.2 Astellas Pharma Business Overview
        11.13.3 Astellas Pharma Ophthalmology Disorders Drug Introduction
        11.13.4 Astellas Pharma Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.13.5 Astellas Pharma Recent Developments
    11.14 Ferrer Corporate
        11.14.1 Ferrer Corporate Company Details
        11.14.2 Ferrer Corporate Business Overview
        11.14.3 Ferrer Corporate Ophthalmology Disorders Drug Introduction
        11.14.4 Ferrer Corporate Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.14.5 Ferrer Corporate Recent Developments
    11.15 Amgen Inc
        11.15.1 Amgen Inc Company Details
        11.15.2 Amgen Inc Business Overview
        11.15.3 Amgen Inc Ophthalmology Disorders Drug Introduction
        11.15.4 Amgen Inc Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.15.5 Amgen Inc Recent Developments
    11.16 Editas Medicine Inc
        11.16.1 Editas Medicine Inc Company Details
        11.16.2 Editas Medicine Inc Business Overview
        11.16.3 Editas Medicine Inc Ophthalmology Disorders Drug Introduction
        11.16.4 Editas Medicine Inc Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.16.5 Editas Medicine Inc Recent Developments
    11.17 ProQR Therapeutics NV
        11.17.1 ProQR Therapeutics NV Company Details
        11.17.2 ProQR Therapeutics NV Business Overview
        11.17.3 ProQR Therapeutics NV Ophthalmology Disorders Drug Introduction
        11.17.4 ProQR Therapeutics NV Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.17.5 ProQR Therapeutics NV Recent Developments
    11.18 ReNeuron
        11.18.1 ReNeuron Company Details
        11.18.2 ReNeuron Business Overview
        11.18.3 ReNeuron Ophthalmology Disorders Drug Introduction
        11.18.4 ReNeuron Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.18.5 ReNeuron Recent Developments
    11.19 Amarantus BioScience
        11.19.1 Amarantus BioScience Company Details
        11.19.2 Amarantus BioScience Business Overview
        11.19.3 Amarantus BioScience Ophthalmology Disorders Drug Introduction
        11.19.4 Amarantus BioScience Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.19.5 Amarantus BioScience Recent Developments
    11.20 Ocugen
        11.20.1 Ocugen Company Details
        11.20.2 Ocugen Business Overview
        11.20.3 Ocugen Ophthalmology Disorders Drug Introduction
        11.20.4 Ocugen Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.20.5 Ocugen Recent Developments
    11.21 ReGenX Biosciences
        11.21.1 ReGenX Biosciences Company Details
        11.21.2 ReGenX Biosciences Business Overview
        11.21.3 ReGenX Biosciences Ophthalmology Disorders Drug Introduction
        11.21.4 ReGenX Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.21.5 ReGenX Biosciences Recent Developments
    11.22 Sucampo Pharmaceuticals
        11.22.1 Sucampo Pharmaceuticals Company Details
        11.22.2 Sucampo Pharmaceuticals Business Overview
        11.22.3 Sucampo Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.22.4 Sucampo Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.22.5 Sucampo Pharmaceuticals Recent Developments
    11.23 Orphagen Pharmaceuticals
        11.23.1 Orphagen Pharmaceuticals Company Details
        11.23.2 Orphagen Pharmaceuticals Business Overview
        11.23.3 Orphagen Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.23.4 Orphagen Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.23.5 Orphagen Pharmaceuticals Recent Developments
    11.24 Okuvision
        11.24.1 Okuvision Company Details
        11.24.2 Okuvision Business Overview
        11.24.3 Okuvision Ophthalmology Disorders Drug Introduction
        11.24.4 Okuvision Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.24.5 Okuvision Recent Developments
    11.25 Second Sight Medical
        11.25.1 Second Sight Medical Company Details
        11.25.2 Second Sight Medical Business Overview
        11.25.3 Second Sight Medical Ophthalmology Disorders Drug Introduction
        11.25.4 Second Sight Medical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.25.5 Second Sight Medical Recent Developments
    11.26 Acucela
        11.26.1 Acucela Company Details
        11.26.2 Acucela Business Overview
        11.26.3 Acucela Ophthalmology Disorders Drug Introduction
        11.26.4 Acucela Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.26.5 Acucela Recent Developments
    11.27 Stealth BioTherapeutics
        11.27.1 Stealth BioTherapeutics Company Details
        11.27.2 Stealth BioTherapeutics Business Overview
        11.27.3 Stealth BioTherapeutics Ophthalmology Disorders Drug Introduction
        11.27.4 Stealth BioTherapeutics Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.27.5 Stealth BioTherapeutics Recent Developments
    11.28 Sun Pharma Advanced Research Company
        11.28.1 Sun Pharma Advanced Research Company Company Details
        11.28.2 Sun Pharma Advanced Research Company Business Overview
        11.28.3 Sun Pharma Advanced Research Company Ophthalmology Disorders Drug Introduction
        11.28.4 Sun Pharma Advanced Research Company Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.28.5 Sun Pharma Advanced Research Company Recent Developments
    11.29 AmpliPhi Biosciences
        11.29.1 AmpliPhi Biosciences Company Details
        11.29.2 AmpliPhi Biosciences Business Overview
        11.29.3 AmpliPhi Biosciences Ophthalmology Disorders Drug Introduction
        11.29.4 AmpliPhi Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.29.5 AmpliPhi Biosciences Recent Developments
    11.30 Applied Genetic Technologies
        11.30.1 Applied Genetic Technologies Company Details
        11.30.2 Applied Genetic Technologies Business Overview
        11.30.3 Applied Genetic Technologies Ophthalmology Disorders Drug Introduction
        11.30.4 Applied Genetic Technologies Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.30.5 Applied Genetic Technologies Recent Developments
    11.31 Asklepios BioPharmaceutical
        11.31.1 Asklepios BioPharmaceutical Company Details
        11.31.2 Asklepios BioPharmaceutical Business Overview
        11.31.3 Asklepios BioPharmaceutical Ophthalmology Disorders Drug Introduction
        11.31.4 Asklepios BioPharmaceutical Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.31.5 Asklepios BioPharmaceutical Recent Developments
    11.32 Biovista
        11.32.1 Biovista Company Details
        11.32.2 Biovista Business Overview
        11.32.3 Biovista Ophthalmology Disorders Drug Introduction
        11.32.4 Biovista Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.32.5 Biovista Recent Developments
    11.33 Spark Therapeutics
        11.33.1 Spark Therapeutics Company Details
        11.33.2 Spark Therapeutics Business Overview
        11.33.3 Spark Therapeutics Ophthalmology Disorders Drug Introduction
        11.33.4 Spark Therapeutics Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.33.5 Spark Therapeutics Recent Developments
    11.34 Caladrius Biosciences
        11.34.1 Caladrius Biosciences Company Details
        11.34.2 Caladrius Biosciences Business Overview
        11.34.3 Caladrius Biosciences Ophthalmology Disorders Drug Introduction
        11.34.4 Caladrius Biosciences Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.34.5 Caladrius Biosciences Recent Developments
    11.35 Dompe Farmaceutici
        11.35.1 Dompe Farmaceutici Company Details
        11.35.2 Dompe Farmaceutici Business Overview
        11.35.3 Dompe Farmaceutici Ophthalmology Disorders Drug Introduction
        11.35.4 Dompe Farmaceutici Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.35.5 Dompe Farmaceutici Recent Developments
    11.36 Dormant Projects
        11.36.1 Dormant Projects Company Details
        11.36.2 Dormant Projects Business Overview
        11.36.3 Dormant Projects Ophthalmology Disorders Drug Introduction
        11.36.4 Dormant Projects Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.36.5 Dormant Projects Recent Developments
    11.37 Grupo Ferrer Internacional
        11.37.1 Grupo Ferrer Internacional Company Details
        11.37.2 Grupo Ferrer Internacional Business Overview
        11.37.3 Grupo Ferrer Internacional Ophthalmology Disorders Drug Introduction
        11.37.4 Grupo Ferrer Internacional Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.37.5 Grupo Ferrer Internacional Recent Developments
    11.38 ID Pharma
        11.38.1 ID Pharma Company Details
        11.38.2 ID Pharma Business Overview
        11.38.3 ID Pharma Ophthalmology Disorders Drug Introduction
        11.38.4 ID Pharma Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.38.5 ID Pharma Recent Developments
    11.39 InFlectis BioScience
        11.39.1 InFlectis BioScience Company Details
        11.39.2 InFlectis BioScience Business Overview
        11.39.3 InFlectis BioScience Ophthalmology Disorders Drug Introduction
        11.39.4 InFlectis BioScience Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.39.5 InFlectis BioScience Recent Developments
    11.40 Ionis Pharmaceuticals
        11.40.1 Ionis Pharmaceuticals Company Details
        11.40.2 Ionis Pharmaceuticals Business Overview
        11.40.3 Ionis Pharmaceuticals Ophthalmology Disorders Drug Introduction
        11.40.4 Ionis Pharmaceuticals Revenue in Ophthalmology Disorders Drug Business (2017-2022)
        11.40.5 Ionis Pharmaceuticals Recent Developments
    11.41 Ixchel Pharma
    11.42 Khondrion
    11.43 Mimetogen Pharmaceuticals
    11.44 Mitotech
    11.45 M's Science
    11.46 Nanovector
    11.47 SanBio
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Ophthalmology Disorders Drug Market